U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07226570) titled 'Mapping Ibogaine Neural Dynamics in Opioid Use Disorder' on Oct. 22.
Brief Summary: This study aims to understand how ibogaine treatment may change brain activity and symptoms in people with moderate-severe opioid use disorder (OUD), as defined by the DSM-5. Ibogaine is a plant-derived compound that some studies suggest can reduce opioid cravings and withdrawal. Participants in this study will already be independently scheduled to receive legal ibogaine treatment at a licensed clinic outside of the U.S. The University of California, Irvine (UCI) research team will not provide the treatment but will conduct brain imaging, administer ...